FDA's Office of Surveillance and Biometrics
This article was originally published in The Gray Sheet
Executive SummaryDevice center office disbands its Division of Biometric Sciences in a restructuring effective Aug. 1. Two of the division's three branches, epidemiology (eight members) and postmarket studies (6 members), have been moved to OSB's Division of Postmarket Evaluation. The Statistics Branch (19 members) has been elevated to division status, with branch chief Harry Bushar acting as director for a 90-day detail. Creation of the Biostatistics Division, according to FDA staffers, anticipates the need for a larger statistics staff under a device user fee program. The entire restructuring must be finalized by center Director Bruce Burlington, which could occur within the next three months
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.